Poxel Announces Upcoming Participation at the JMP Securities Life Science Conference
11 Mai 2023 - 7:30AM
Business Wire
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage
biopharmaceutical company developing innovative treatments for
chronic serious diseases with metabolic pathophysiology, including
non-alcoholic steatohepatitis (NASH) and rare metabolic disorders,
today announced its participation at the JMP Securities Life
Science Conference, to be held in New York, NY, Monday, May 15, and
Tuesday, May 16, 2023.
Thomas Kuhn, CEO of Poxel, will be available for one-on-one
virtual meetings on May 15, 2023. The Company’s virtual
presentation is scheduled for May 15 at 12:30 pm ET.
About Poxel SA
Poxel is a clinical stage biopharmaceutical company
developing innovative treatments for chronic serious diseases
with metabolic pathophysiology, including non-alcoholic
steatohepatitis (NASH) and rare disorders. For the treatment of
NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its
primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In
rare diseases, development of PXL770, a first-in-class
direct adenosine monophosphate-activated protein kinase (AMPK)
activator, is focused on the treatment of adrenoleukodystrophy
(ALD) and autosomal dominant polycystic kidney disease (ADPKD).
TWYMEEG® (Imeglimin), Poxel’s first-in-class product that
targets mitochondrial dysfunction, is marketed for the treatment of
type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to
receive royalties and sales-based payments. Poxel has a strategic
partnership with Sumitomo Pharma for Imeglimin in Japan, China, and
eleven other Asian countries. Listed on Euronext Paris, Poxel is
headquartered in Lyon, France, and has subsidiaries in Boston, MA,
and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230510005909/en/
Contacts - Investor relations / Media Aurélie Bozza
Investor Relations & Communication Senior Director
aurelie.bozza@poxelpharma.com +33 6 99 81 08 36 Elizabeth Woo
Senior Vice President, Investor Relations & Communication
elizabeth.woo@poxelpharma.com NewCap Nicolas Fossiez and Arthur
Rouillé poxel@newcap.eu +33 1 44 71 94 94
Poxel (EU:POXEL)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Poxel (EU:POXEL)
Historical Stock Chart
Von Mai 2023 bis Mai 2024